Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. - Wikidata - wikimedia - TriplyDB

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

http://www.wikidata.org/entity/Q43547525

about

Management of borderline resectable pancreatic cancer Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Management of periampullary adenocarcinoma by pancreaticoduodenectomy at a regional teaching hospital.Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplina Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.The role of radiotherapy in multimodal treatment of pancreatic carcinoma Expression of Gli1 and Wnt2B correlates with progression and clinical outcome of pancreatic cancer.Pancreatic adenocarcinoma Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expr S-1 in the treatment of pancreatic cancer.Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft.The plasma fraction of stored erythrocytes augments pancreatic cancer metastasis in male versus female mice.Gender-specific transfusion affects tumor-associated neutrophil: macrophage ratios in murine pancreatic adenocarcinoma.The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment.Current status of adjuvant therapy for pancreatic cancer.Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States.Surgical management of early-stage pancreatic cancer.Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?Emerging drugs in pancreatic cancer.Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival.Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy The role of radiotherapy in management of pancreatic cancer A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.Current state of adjuvant therapy in resected pancreatic adenocarcinoma.Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology.Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.

P2860

Q26781445-FF3B363F-9240-40D2-8A1C-CA20D30ADF87 Q28729144-26A4C34C-6E0B-44A7-BD60-DFC702A3FBC6 Q30238706-5227DBFE-3AF5-4D7C-8430-BFFD3CE47709 Q30278871-1E4E1376-CC84-4FEB-A2BF-688B0D3265FD Q30726275-C5226585-1531-4738-834C-F003D856E7A7 Q33276956-D0D4ECCB-C52A-4998-9102-1A7D89DE6F4D Q33431711-5905538A-3722-4B16-8E20-F7D463A28833 Q33750803-5019D901-8B9E-46E4-9E2C-EF720D36A86C Q33816747-D7986C18-F64F-4691-AF31-953CAE1FFBBD Q33820788-0E748B35-C952-473E-876A-0A2248D14B90 Q33905392-0D4145D5-D845-4C19-BE0F-CFBC3942AC4E Q34025910-7A6C3ED0-E39B-47CF-8EF2-E19D50195F79 Q34029423-09417886-69DF-4D0F-91BD-CEA2FB700551 Q34140498-C5032BFF-9560-4717-A6D1-A613012A2769 Q34224734-3C409D51-B42B-4F17-A849-51E829A6D4D8 Q34286070-E4CDFF2C-F37D-4651-989C-DC602507CF18 Q34374721-3696CBEC-63BC-4874-9D9D-75596B86B2B1 Q34408283-73A473AA-8C0F-4602-9CE6-A9B0CBB985D7 Q34467156-8CDD0AB8-4688-4D0F-9831-3D40728A3964 Q34732306-6A2D6256-BEF6-465F-9E4C-2D55FA055B1B Q34986932-B1B5EB2F-D36E-4149-B07E-31940DBE9F54 Q35059946-E2C6F549-B442-42D0-ABF6-B676E1C00C82 Q35097390-212DCF93-AB9B-44F7-A72D-3782A79A051C Q35097399-9C9A5EDE-0E27-47DF-A7C0-6BD0D997DDA8 Q35186758-3379F697-17D9-479E-B0FD-7729C35D183D Q35583760-C7697898-E573-45CE-AAB4-B697411A0100 Q35603860-8C5AEF76-A17F-4DC4-B5DB-C997ACF88988 Q35641993-DD728C43-ED0C-4AFB-8C58-32129555CA99 Q35776229-808A67F1-9C7C-4B26-9F10-D1EC57F17014 Q35779283-134F62BA-2998-431E-B1F3-1A6ACC610A6C Q35790591-90C27166-ACB6-4E75-8DC0-92F1E6CE5F0F Q35820525-5652B781-0AD8-45E7-B164-B32945A5B112 Q35968248-57793BEC-D6D5-45EB-8F35-FA4BC188C58A Q36097189-2BBC63FC-F83C-43E3-85A6-7613D0193778 Q36130588-A1BCDA9B-74FA-45C9-9CEC-32E5FC4572D0 Q36195812-D2598944-DD77-4E99-ADB4-48A57D5EA408 Q36425150-F705D3A6-C5B7-4235-96B9-8EE30AE404C4 Q36569189-83ADAACB-083B-4948-BC77-5D925B144084 Q36580127-DA553A8E-223A-43D3-9354-38C85155DDAF Q36666622-226BEC9B-87A7-4A7A-B077-D837B1659640

P2860

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

http://www.wikidata.org/entity/Q43547525

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@en

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@nl

type

label

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@en

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@nl

prefLabel

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@en

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@nl

P1433

Q43547525-3CED1267-BE15-4148-9719-1E332EDC6531

P1476

Q43547525-56957662-AEE8-4FDB-A865-E5E3FA832D15

P2093

Q43547525-10572EAA-37A2-4818-8D0D-8F96B920938F

Q43547525-2C2C29FB-D8DD-4C7B-9708-ABFDB971C600

Q43547525-3DE729AA-08C9-4887-BEC8-725144A0C576

Q43547525-6329C3EE-6630-4497-B80B-4BB255112873

Q43547525-74F116F0-D087-45A7-80FE-F1E9375B708B

Q43547525-754E8C4A-6737-4A48-80BD-6E90D3ED8479

Q43547525-8B58D589-BA8F-4C72-A997-D28EE26212BD

Q43547525-9A4B5AD4-4A5C-43A6-A8ED-8E182765FF0C

Q43547525-BC7F75E7-1F22-4A83-A403-66C340806564

Q43547525-CCFAB6D5-B569-4E0A-B47A-89A8EE0A9BFC

P2888

Q43547525-3B7C7823-0C1A-40C2-AF1C-D55D1B231C72

P304

Q43547525-87738EC0-C7C8-4586-A8C6-AC82A89BEBA4

P31

Q43547525-B4A95B36-0013-4276-BA85-50979284DAC6

P356

Q43547525-68F0D8D2-6169-4DE1-B428-C25D1D1462B5

P433

Q43547525-4A711CA8-F1B8-499A-84B1-8B35F9902CAD

P478

Q43547525-1840311A-6204-48CB-990A-846C2C094796

P577

Q43547525-8DDCC788-0439-4EF2-8706-21966797E261

P5875

Q43547525-CB52DD71-522E-4BE2-B96D-80A997820D2C

P6179

Q43547525-E5050602-A79F-4332-94AE-CE499CD611B3

P698

Q43547525-C8AFE57E-0B85-43F4-8994-303DCC676EBC

P921

Q43547525-287EA674-9F16-4154-BD39-A150B67333F9

Q43547525-3EFCA0BB-D6FD-44E2-8620-4FF76EC7B059

Q43547525-E8FDD5F7-E6B3-4573-989C-30150879413F

P356

S10434-001-0123-4

P1433

Annals of Surgical Oncology

P1476

Neoadjuvant chemoradiotherapy ...... riables and survival duration.

@en

P2093

A P Dackiw

http://www.w3.org/2001/XMLSchema#string

C H Crane

http://www.w3.org/2001/XMLSchema#string

D B Evans

http://www.w3.org/2001/XMLSchema#string

D B Harbison

http://www.w3.org/2001/XMLSchema#string

J E Lee

http://www.w3.org/2001/XMLSchema#string

J L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

J N Vauthey

http://www.w3.org/2001/XMLSchema#string

K R Cleary

http://www.w3.org/2001/XMLSchema#string

K R Hess

http://www.w3.org/2001/XMLSchema#string

M E Jean

http://www.w3.org/2001/XMLSchema#string

P2888

s10434-001-0123-4

P304

123-132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10434-001-0123-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225450054

http://www.w3.org/2001/XMLSchema#string

P6179

1021293466

http://www.w3.org/2001/XMLSchema#string

P698

11258776

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

Aizkuņģa dziedzeris